# A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions

> **NCT03843541** · PHASE3 · COMPLETED · sponsor: **Zambon SpA** · enrollment: 333 (actual)

## Conditions studied

- Respiratory Tract Diseases
- Abnormal Mucus Secretions

## Interventions

- **DRUG:** N-acetylcysteine (NAC) 600 mg
- **DRUG:** Ambroxol hydrochloride 30 mg
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03843541
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-25
- **Primary completion:** 2021-01-23
- **Final completion:** 2021-02-05
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03843541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03843541, "A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03843541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*